This High-Yielding Stock Just Increased Its Dividend Again
Sun Life Financial (TSX:SLF)(NYSE:SLF) announced a 5% increase to its quarterly dividend on May 8, raising its quarterly payout from $0.84 to $0.88 per share. The company has routinely increased its dividend payments over the years and been a solid income stock to hang on to. Back in June 2015, Sun Life’s quarterly dividend was $0.38, which means this upcoming payout is an increase of more than 131% since then; that averages out to a compounded annual growth rate of 8.8%. That’s a healthy rate of annual increase for investors, and gives them a good incentive to remain committed to the stock. Today, with the increase, Sun Life’s stock yields just over 4%, making it one of the higher-yielding stocks you can buy on the TSX, which doesn’t come up with significant risk. Last year, the company reported more than $3 billion in earnings on revenue totaling $36.8 billion, for a profit margin of over 8%. The company has $1.55 trillion in assets under management with operations in multiple countries, including Canada, the U.S., and a strong presence in Asia. At a time when investors are concerned about uncertainty in the markets, Sun Life can be a stock that can be a safe haven. This year, it has risen by around 3%. And while that isn’t a spectacular performance, what’s important is that it has been stable; the S&P 500 remains in negative territory. If you’re a dividend investor or just want some safety and stability, Sun Life can be an excellent option to consider for your portfolio today.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


